Telavancin for Hospital-Acquired Pneumonia: Clinical Response and 28-Day Survival

Telavancin versus Vancomycin for Hospital-Acquired Pneumonia due to Gram-positive Pathogens

(2010) E. Rubinstein et al.   CLINICAL INFECTIOUS DISEASES

Reduced Vancomycin Susceptibility in Staphylococcus aureus, Including Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Strains: Resistance Mechanisms, Laboratory Detection, and Clinical Implications

(2010) B. P. Howden et al.   CLINICAL MICROBIOLOGY REVIEWS

Clinical Outbreak of Linezolid-Resistant Staphylococcus aureus in an Intensive Care Unit

(2010) Miguel Sánchez García   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Telavancin Disrupts the Functional Integrity of the Bacterial Membrane through Targeted Interaction with the Cell Wall Precursor Lipid II

(2009) C. S. Lunde et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro Activity of Telavancin against Resistant Gram-Positive Bacteria

(2008) K. M. Krause et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pneumonia Caused by Methicillin‐ResistantStaphylococcus aureus

(2008) Ethan Rubinstein et al.   CLINICAL INFECTIOUS DISEASES

Acute kidney injury criteria predict outcomes of critically ill patients*

(2008) Fidel Barrantes et al.   CRITICAL CARE MEDICINE